ADALIMUMAB
Information current as at: 1 October 2024
The pharmaceutical company has advised that it is not proceeding in the PBS listing process at this time. The process for listing this medicine has ceased.
Submission Details
- Brand name:
-
- Hulio®
- Pharmaceutical company:
- Alphapharm Pty Ltd
- Condition/indication:
(therapeutic use) -
- Severe Crohn disease; Moderate to severe ulcerative colitis; Severe active juvenile idiopathic arthritis; Complex refractory fistulising Crohn disease; Severe active rheumatoid arthritis; Severe psoriatic arthritis; Ankylosing spondylitis; Severe chronic plaque psoriasis; Moderate to severe hidradenitis suppurativa.
- PBAC Submission type:
- New listing (–)
- Comment:
- --
- Public Summary Document:
- Public Summary Documents – November 2021
- Related medicines:
- --
Progress Details
-
Submission received for: - November 2021 PBAC meeting
-
Opportunity for consumer comment: - Open 28/07/2021 and close 22/09/2021 (see PBS Website)
-
PBAC meeting: - Held on 03/11/2021
-
Lodgement of required documentation: - 28/02/2022
-
Acceptance of complete documentation:
- Accepted
-
Agreement to listing arrangements: - Commenced on 08/03/2022
-
Status:
- Finalised
-
Government processes: - Not applicable
-
Medicine listed on the PBS: - Not applicable
Case ID: a391
Page last updated: 02 May 2024